Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

35 U.S.C. § 112, First Paragraph By: Sheetal S. Patel.
Rule 105 Requirements in Plant Patent Applications Bruce Campell Supervisory Patent Examiner Art Unit
INTELLECTUAL PROPERTY PROTECTION OFFICE OF PATENT COUNSEL March 16, 2001.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
October 2007KSR Training1 TC 3700 KSR Sample Rejection.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting October 8, 2002 William F. Smith Administrative Patent Judge Board of Patent Appeals.
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
Patent, Trademark, Copyright, and Enforcement - Law and Policy November 5-8, 2007 United States Patent and Trademark Office Global Intellectual Property.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Filing Compliant Reexam Requests Andy Kashnikow SPE, Central Reexamination Unit Andy Kashnikow SPE, Central Reexamination Unit June, 2010.
1 Principles in Restriction Practice TC 1600 Anthony Caputa TC Practice Specialist (571)
Memorandum - 35 U.S.C. 112, Second and Sixth Paragraphs Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Intellectual Property March 4, 2015 Don Keach Director, Intellectual Property Development and Technology Transfer Office Copyright University of Kentucky.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Greg H. Gardella Ex Parte and Inter Partes Reexamination Tactics AIPLA 2010 Winter Institute.
Graham v John Deere Patent Law. Justice Tom Clark ( )
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
Drafting the Best Possible Claims Andrew J. Dillon.
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biological Deposits.
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
©2011 Haynes and Boone, LLP 1 Functional Language in Claims David O’Dell Haynes and Boone LLP
1 Patent Law in the Age of IoT The Landscape Has Shifted. Are You Prepared? 1 Jeffrey A. Miller, Esq.
Routine Optimization Jean Witz, tQAS, TC
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
19/19/07132 Declarations 37 CFR § Practice GENERAL INTRODUCTION.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Further Research Considerations April 30, Further Research & Development Considerations April 30, 2015.
Hamre, Schumann, Mueller & Larson, P.C U.S. Patent Claims By James A. Larson.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
UNITED STATES PATENT AND TRADEMARK OFFICE
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Patenting Interfering RNA John LeGuyader – SPE Art Unit 1635 (571)
Claims, Anticipation, and Obviousness Kathleen Kahler Fonda Legal Advisor, Office of Patent Legal Administration July 30, 2010.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biological Deposits.
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Margaret Polson Polson Intellectual Property Law, PC US Design Patents Overview.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
(c) 2004, David Schnapf, Sheppard Mullin Richter & Hampton LLP 1 Examiner Use of Background Statements David Schnapf Sheppard Mullin Richter & Hampton.
BLW 360 – January 27, 2015 Jonathan LA Phillips
10/13/081 PARK - SPEC SAME IN APP & PAT The Specification: Application v. Issued Patent Why is the specification in the application almost exactly identical.
Introduction to Intellectual Property Class of Sept
PATC Module 2 – Infringement/Validity
Processes Which Employ Non-Obvious Products
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Global Innovation Management Workout on Writing a Patent
Quality Assurance Specialist
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
Stem Cells Peter Paras, Jr.
International/Foreign Activities
A tutorial and update on patentable subject matter
What You Didn’t Know That You Didn’t Know About Patents
Examination Practice in Applications Presenting “Reach-Through Claims”
Presentation transcript:

Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616

Prior Art Reference is Presumed to be Enabled When the reference relied on expressly anticipates or makes obvious all of the elements of the claimed invention, the reference is presumed to be operable. Once such a reference is found, the burden shifts to the applicant to provide facts rebutting the presumption of operability. In re Sasse, 629 F.2d 675, 681 (Fed. Cir. 1980) See also MPEP

Meaning of “Enabling Disclosure” is Independent of the Type of Disclosure Level of disclosure required for a prior art reference to be an “enabling disclosure” is the same no matter what type of art is at issue It does not matter whether the prior art is a U.S. patent, foreign patent, or printed publication No basis in 35 USC 102 or 103 for discrimination either in favor of or against prior art references on the basis of nationality In re Moreton, 288 F.2d 708, 711, (CCPA 1961)

35 U.S.C 102 Reference Must Enable Without Undue Experimentation Elan Pharm., Inc. v. Mayo Foundation for Medical and Education Research, 346 F.3d 1051, 1054, (Fed. Cir. 2003) CAFC remanded the case back to the district court for determination of whether the prior art reference enabled persons of ordinary skill in the field to make the desired mutated mouse without undue experimentation,

Reference is Enabling if.... Public was in possession of the claimed invention “Such possession is effected if one of ordinary skill in the art could have combined the publication’s description of the invention with his [or her] own knowledge to make the claimed invention.” In re Donohue, 766 F.2d 531, 533 (Fed. Cir. 1985)

35 U.S.C. 102 Rejections with Additional References Establishing Enablement An examiner may make a 35 U.S.C. 102 rejection over a reference which teaches every element of the invention but not does enable how to make or use. Secondary references may be used to establish public possession of the method of making and/or using. In re Donohue, 766 F.2d 531, 534 (Fed. Cir. 1985)

When the Reference Only Discloses the Structure of the Compound Lack of enabling disclosure may be established by evidence that attempts to make the compound were unsuccessful. In re Wiggins, 488 F.2d 538, 542 – 543 (CCPA 1973)

When the Reference Only Discloses the Structure of the Compound It is not necessary that an invention disclose under 35 U.S.C. 102 shall have actually been made in order to satisfy the enablement requirement. In re Donohue, 766 F.2d 531, 533 (Fed. Cir. 1985)

When the Reference Only Discloses the Structure of the Compound In Donohue the examiner made a rejection 35 U.S.C. 102 over a publication which disclosed the compound along with two patents which taught a general process of preparing the specific class of compounds. Applicant provided an affidavit stating that the publication did not actually show the synthesis of the compound—deemed insufficient evidence to overcome rejection under 35 U.S.C. 102

35 U.S.C 103 Rejection Over Obvious Homologs In re Hoeksema, 399 F.2d 269 (CCPA 1968) The examiner rejected a claim to a compound using a patent (De Boer) which disclosed homologs and process of making them. Applicant overcame rejection with affidavit by expert who stated that the process disclosed in the patent could not be used to make the claimed compound.

What Constitutes Enabling Prior Art for Plants? When the claims are directed to plants, the reference combined with the knowledge in the prior art, must enable one of ordinary skill in the art to reproduce the plant. In re LeGrice, 301 F.2d 929 (CCPA 1962) The examiner rejected the claimed rose on the basis of a catalogue which only disclosed pictures of the plant and stated that the person had raised the roses.

What Constitutes Enabling Prior Art for Plants?(cont’d) In LeGrice there was no evidence of commercial availability in enabling form since the asexually reproduced rose could not be reproduced from seed. In contrast in Ex parte Thompson, 24 USPQ2d 1618 (Bd. Pat. App. & Inter. 1992) seeds were commercially available to grow the cotton cultivar.

Pictures May be Enabling Prior Art References Pictures and drawings may be enabling to put the public in the possession of the article pictured. However, the picture must show all of the claimed structural features and how they are put together. Jockmus v. Leviton, 28 F.2d 812 (2d Cir. 1928)

35 U.S.C. 102 Reference does not Require a Patentable Utility “[N]o utility need be disclosed for a reference to be anticipatory of a claim to an old compound.” In re Schoenwald, F.2d 1122, 1124 (Fed. Cir. 1992). It is enough that the claimed compound is taught by the reference.

Summary of Ways to Attack Prior Art References as Non- enabling Establish that the prior art tried and failed to make the compound Provide declaration by an expert that the disclosure of the reference, even with the knowledge in the art, was insufficient to permit the artisan to make the compound.